These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

557 related articles for article (PubMed ID: 24131709)

  • 1. Chronic joint disease caused by persistent Chikungunya virus infection is controlled by the adaptive immune response.
    Hawman DW; Stoermer KA; Montgomery SA; Pal P; Oko L; Diamond MS; Morrison TE
    J Virol; 2013 Dec; 87(24):13878-88. PubMed ID: 24131709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chikungunya Virus Evades Antiviral CD8
    Davenport BJ; Bullock C; McCarthy MK; Hawman DW; Murphy KM; Kedl RM; Diamond MS; Morrison TE
    J Virol; 2020 Apr; 94(9):. PubMed ID: 32102875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chikungunya disease: infection-associated markers from the acute to the chronic phase of arbovirus-induced arthralgia.
    Dupuis-Maguiraga L; Noret M; Brun S; Le Grand R; Gras G; Roques P
    PLoS Negl Trop Dis; 2012; 6(3):e1446. PubMed ID: 22479654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A high-dose inoculum size results in persistent viral infection and arthritis in mice infected with chikungunya virus.
    Zhang Y; Yan H; Li X; Zhou D; Zhong M; Yang J; Zhao B; Fan X; Fan J; Shu J; Lu M; Jin X; Zhang E; Yan H
    PLoS Negl Trop Dis; 2022 Jan; 16(1):e0010149. PubMed ID: 35100271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chikungunya viruses that escape monoclonal antibody therapy are clinically attenuated, stable, and not purified in mosquitoes.
    Pal P; Fox JM; Hawman DW; Huang YJ; Messaoudi I; Kreklywich C; Denton M; Legasse AW; Smith PP; Johnson S; Axthelm MK; Vanlandingham DL; Streblow DN; Higgs S; Morrison TE; Diamond MS
    J Virol; 2014 Aug; 88(15):8213-26. PubMed ID: 24829346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clearance of Chikungunya Virus Infection in Lymphoid Tissues Is Promoted by Treatment with an Agonistic Anti-CD137 Antibody.
    Hong JP; McCarthy MK; Davenport BJ; Morrison TE; Diamond MS
    J Virol; 2019 Dec; 93(24):. PubMed ID: 31578287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chikungunya Virus Exposure Partially Cross-Protects against Mayaro Virus Infection in Mice.
    Fumagalli MJ; de Souza WM; de Castro-Jorge LA; de Carvalho RVH; Castro ÍA; de Almeida LGN; Consonni SR; Zamboni DS; Figueiredo LTM
    J Virol; 2021 Nov; 95(23):e0112221. PubMed ID: 34549980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chikungunya virus infection results in higher and persistent viral replication in aged rhesus macaques due to defects in anti-viral immunity.
    Messaoudi I; Vomaske J; Totonchy T; Kreklywich CN; Haberthur K; Springgay L; Brien JD; Diamond MS; Defilippis VR; Streblow DN
    PLoS Negl Trop Dis; 2013; 7(7):e2343. PubMed ID: 23936572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Rodent Model of Chikungunya Virus Infection in RAG1 -/- Mice, with Features of Persistence, for Vaccine Safety Evaluation.
    Seymour RL; Adams AP; Leal G; Alcorn MD; Weaver SC
    PLoS Negl Trop Dis; 2015; 9(6):e0003800. PubMed ID: 26115459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pathogenic role for CD4+ T cells during Chikungunya virus infection in mice.
    Teo TH; Lum FM; Claser C; Lulla V; Lulla A; Merits A; Rénia L; Ng LF
    J Immunol; 2013 Jan; 190(1):259-69. PubMed ID: 23209328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon-alpha/beta deficiency greatly exacerbates arthritogenic disease in mice infected with wild-type chikungunya virus but not with the cell culture-adapted live-attenuated 181/25 vaccine candidate.
    Gardner CL; Burke CW; Higgs ST; Klimstra WB; Ryman KD
    Virology; 2012 Apr; 425(2):103-12. PubMed ID: 22305131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Caribbean and La Réunion Chikungunya Virus Isolates Differ in Their Capacity To Induce Proinflammatory Th1 and NK Cell Responses and Acute Joint Pathology.
    Teo TH; Her Z; Tan JJ; Lum FM; Lee WW; Chan YH; Ong RY; Kam YW; Leparc-Goffart I; Gallian P; Rénia L; de Lamballerie X; Ng LF
    J Virol; 2015 Aug; 89(15):7955-69. PubMed ID: 25995257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A mouse model of chikungunya virus-induced musculoskeletal inflammatory disease: evidence of arthritis, tenosynovitis, myositis, and persistence.
    Morrison TE; Oko L; Montgomery SA; Whitmore AC; Lotstein AR; Gunn BM; Elmore SA; Heise MT
    Am J Pathol; 2011 Jan; 178(1):32-40. PubMed ID: 21224040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistent chronic inflammation and infection by Chikungunya arthritogenic alphavirus in spite of a robust host immune response.
    Hoarau JJ; Jaffar Bandjee MC; Krejbich Trotot P; Das T; Li-Pat-Yuen G; Dassa B; Denizot M; Guichard E; Ribera A; Henni T; Tallet F; Moiton MP; Gauzère BA; Bruniquet S; Jaffar Bandjee Z; Morbidelli P; Martigny G; Jolivet M; Gay F; Grandadam M; Tolou H; Vieillard V; Debré P; Autran B; Gasque P
    J Immunol; 2010 May; 184(10):5914-27. PubMed ID: 20404278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chikungunya Virus-Induced Arthritis: Role of Host and Viral Factors in the Pathogenesis.
    Amdekar S; Parashar D; Alagarasu K
    Viral Immunol; 2017 Dec; 30(10):691-702. PubMed ID: 28910194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Residue 82 of the Chikungunya virus E2 attachment protein modulates viral dissemination and arthritis in mice.
    Ashbrook AW; Burrack KS; Silva LA; Montgomery SA; Heise MT; Morrison TE; Dermody TS
    J Virol; 2014 Nov; 88(21):12180-92. PubMed ID: 25142598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dermal and muscle fibroblasts and skeletal myofibers survive chikungunya virus infection and harbor persistent RNA.
    Young AR; Locke MC; Cook LE; Hiller BE; Zhang R; Hedberg ML; Monte KJ; Veis DJ; Diamond MS; Lenschow DJ
    PLoS Pathog; 2019 Aug; 15(8):e1007993. PubMed ID: 31465513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deciphering the protective role of adaptive immunity to CHIKV/IRES a novel candidate vaccine against Chikungunya in the A129 mouse model.
    Chu H; Das SC; Fuchs JF; Suresh M; Weaver SC; Stinchcomb DT; Partidos CD; Osorio JE
    Vaccine; 2013 Jul; 31(33):3353-60. PubMed ID: 23727003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-mediated enhancement aggravates chikungunya virus infection and disease severity.
    Lum FM; Couderc T; Chia BS; Ong RY; Her Z; Chow A; Leo YS; Kam YW; Rénia L; Lecuit M; Ng LFP
    Sci Rep; 2018 Jan; 8(1):1860. PubMed ID: 29382880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon Alpha, but Not Interferon Beta, Acts Early To Control Chronic Chikungunya Virus Pathogenesis.
    Locke MC; Fox LE; Dunlap BF; Young AR; Monte K; Lenschow DJ
    J Virol; 2022 Jan; 96(1):e0114321. PubMed ID: 34668781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.